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Summary
Background. — Patent foramen ovale is an anomaly responsible for paradoxical embolizations
and cerebral ischemic events.
Aims. — We want to show second harmonic transthoracic echography sensitized by contrast
agent perfusion is as well as transesophageal echography to patent foramen ovale detection. 
Methods. — Onene hundred twenty one patients referred for transesophageal echocardiography
for patent foramen ovale detection, underwent additive second harmonic transthoracic
echocardiography with one of three randomized contrast agents: a mixture A of dextrose and
air, mixture B of dextrose and air and blood , or mixture C of hydroxyethylamidon. The severity
of atrial shunting was evaluated on recordings by semi-quantitative scoring. Intensity of
contrast was also assessed by objective quantitative videodensitometry.
Results. — No difference was observed between the two techniques, nor between mixture A, B
and C in terms of PFO detection during each exam. However, quantitative contrast analysis
showed higher intensity with mixtures B and C with mixture A during transthoracic echography.
Conclusions. — When performed with a contrast agent, second harmonic transthoracic
echography and transoesophageal echography are comparable when it comes to patent
foramen ovale detection. Although the composition of the contrast agent does not appear to
affect the rate of this detection, contrast quality in the right atrium during transthoracic exam
is better with mixtures B and C than with mixture A.
© 2008 Published by Elsevier Masson SAS.
Resumé
Pré requis. — La perméabilité du foramen ovale est une anomalie responsable d’embolies
paradoxales et d’accidents ischémiques cérébraux.
Buts. — Nous voulons démontrer que l’échocardiographie transthoracique en seconde harmonique
avec produit de contraste est aussi efficace que l’échocardiographie transœsophagienne pour
diagnostiquer un foramen ovale perméable.
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Méthodes. — Cent vingt et un patients adressés pour recherche de foramen ovale perméable
par échographie transœsophagienne ont aussi bénéficié d’une échographie transthoracique en
seconde harmonique. Ces examens ont été sensibilisés par injection d’un des trois produits de
contraste tiré au sort : produit A (Glucosé et air), produit B (Glucosé et air et sang), ou
produit C (hydroxyéthylamidon). Un enregistrement vidéoscopique permettait de quantifier la
sévérité du shunt atrial (score visuel semi quantitatif), et l’échogénicité du produit de
contraste (score vidéo densitométrique numérisé).
Résultats. — Il n’y a pas de différence entre les deux méthodes pour la détection de foramen
ovale perméable, quel que soit le contraste utilisé. L’analyse quantitative de l’échogénicité du
contraste pendant l’examen transthoracique révèle une supériorité des produits B et C sur le
produit A.
Conclusions. — L’échographie transthoracique en seconde harmonique avec injection de
produit de contraste permet de détecter un foramen ovale perméable aussi bien que la voie
transœsophagienne. Même si la composition du produit ne modifie pas ces résultats, les
produits B et C ont une meilleure échogénicité que le produit A.
© 2008 Published by Elsevier Masson SAS.
Introduction
Patent foramen ovale (PFO) is an anomaly of the atrial sep-
tum, defined as the persistence of an anatomical duct
between the right and the left atrium. It can lead to right-
to-left shunting when pressure in the right heart cavities
rises. PFO is implicated in numerous pathologies in which an
embolism passes from the venous circulation to the systemic
arterial circulation, leading to paradoxical embolization and
cerebral ischemia [1, 2]. There is increasing interest in the
investigation of PFO after ischemic cerebral events [3-5]
because such events are the first cause of disability and the
third cause of mortality in developed countries (with 25%
being repeat events) [6, 7]. A multicenter prospective study
on 581 male and female victims of idiopathic ischemic cere-
bral events showed that the incidence of recurrence on anti-
platelet treatment washigher in those with PFO, especially
when it is associated with an atrial septal aneurysm [8]. Fur-
thermore, PFO can now be repaired by transcutaneous
catheterization and this has been shown to prevent recur-
rence. This enhances the worth of echocardiography before
as well as during and after the procedure [9].
Transesophageal echocardiography (TEE) used to be the
gold standard for diagnosis and follow-up after PFO repair
[10-14] but since second harmonic imaging improved ultra-
sound image quality, transthoracic contrast echocardiogra-
phy using second harmonic imaging (2HTTE) is becoming a
diagnostic alternative for PFO detection, especially as sen-
sitivity can be enhanced by using a contrast agent [15,16].
In the present study 2HTTE is compared with TEE in the
diagnosis of PFO, and the ability of three contrast agents
— dextrose solution and air (DA), dextrose solution and air
and blood (DAB) and hydroxyethylamidon solution (HEA) —
to sensitize shunt detection is also compared.
Methods
Population and study design
We included 130 successive patients referred to our echocar-
diography laboratory for TEE to investigate PFO after a syste-
mic ischemic event, or before an atrial fibrillation ablation
procedure. There was no limitation by age, gender, or ultra-
sonic window. All patients gave their consent for the injec-
tion of contrast agent. From a randomization table, we allo-
cated one of the three contrast agents (DA, DAB or HEA) to
each patient. Each patient was given a 2HTTE examination
with the selected contrast agent followed by TEE with the
same contrast agent. The two examinations were carried out
by the same investigator. All examinations were recorded on
videotapes and simple-blind reviewed by an independent exa-
miner. In cases of disagreement, a third examiner resolved
the issue. The video-recordings were digitized for objective
analysis of the contrast intensity in the right atrium. This
study was approved by an Institutional Review Board.
Instrumentation
Two ultrasound systems were used, namely a Sequoia 256
System® with a 2.5-5 MHz transthoracic probe and a transe-
sophageal multiplane probe (Acuson, Mountain View, Cali-
fornia, USA), and a Sound System 5500® with a 2.5-5 MHz
transthoracic probe and a transesophageal multiplane
probe (Hewlett Packard, Andover, Massachusetts, USA).
Standard 2HTTE and TEE procedures were performed for
each patient in accordance with American Society of Echocar-
diography guidelines. More specifically, when the interatrial
septum was visualized both in 2HTTE (apical four-chamber
view) and TEE (two-atrial view), contrast agent was manually
injected through a 18G catheter into a peripheral vein of the
right arm. The contrast agents were prepared as follows: .DA: 9 mL of 5% dextrose solution, shaken with 1 mL of
ambient air;.DAB: 8 mL of 5% dextrose solution, and 1 mL of patient
blood, shaken with 1 mL of ambient air;.HEA: 10 mL of hydroxyethylamidon without shaking.
Each contrast agent was injected at rest during a cough
manœuvre for both 2HTTE and TEE.
Data analysis
The existence of a right-to-left atrial shunt was defined by
the detection of contrast bubbles in the left atrium within
three cardiac cycles of opacification of the right atrium. A
semi-quantitative evaluation of the shunt was made by the
echographist on the basis of the number of bubbles in the
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left atrium: no bubbles (grade 0), 1-10 bubbles (grade 1),
11-30 bubbles (grade 2), more than 30 bubbles (grade 3).
Echocardiograms were digitzsed before and after contrast
agent injection and quantitative digital analysis of contrast
intensity was performed off-line using special software. To
eliminate ultrasound artefacts compensate for differences
in gain settings and isolate the ultrasound signal coming
from the contrast agent, we calculated a “relative variation
of intensity” (RVI):
RVI=[(maximal contrast value)—(value without contrast)]
/ (value without contrast)
Statistical analysis
The Chi2 test was used to compare the homogeneity of the
three groups. A Kappa test was used to calculate the agree-
ment between 2HTTE and TEE. If κ was less than 0.4, the
agreement was poor; if it was between 0.4 and 0.59, agree-
ment was moderate; if it was between 0.6 and 0.79, agree-
ment was good; and if it was above 0.79, the agreement
was very good. Digitized contrast intensities were compa-
red using the Mann - Whitney test. All tests were two-tailed
and a p value <0.05 was considered significant.
Results
Population
The number of examinations provided at least 30 randomzsed
elements per contrast agent. We retained 121 patients out
of 130 for analysis of agreement, and 116 for RVI analysis.
Three examinations were stopped (because of acute left
heart failure, chest pain and systemic systolic hyperten-
sion); three cases could not be analyzed because of missing
items, and eight ofthe videotape tablerecords were incom-
plete. Overall, there was 7%-10% exclusion, which is unu-
sual for a prospective study.
The main characteristics of the population are listed in
table 1. The three groups were comparable in terms of in
age, gender, indication for TEE, and ultrasound transthora-
cic window (which was good in 67%, medium in 27%, and
poor in 6%).
Agreement between 2HTTE and TEE,
irrespective of contrast agent
TEE detected 22 PFO out of 121 patients (18.2%), while
2HTTE detected 23 PFO (19%), including 19 of the 22 PFO
detected with TEE (table 2). There were four false positi-
ves and three false negatives. The agreement between
TEE and 2HTTE was 94.2%, with a coefficient of agreement
κ of 0.81 (very good agreement). Taking TEE as the refe-
rence, 2HTTE had a sensitivity of 86.4%, a specificity of
96%, a positive predictive value of 82.6%, and a negative
predictive value of 96.9%.
Qualitative agreement between 2HTTE 
and TEE, according to contrast agent
Dextrose solution and air (DA) 
Out of 41 patients, we detected 6 PFO with TEE (14.6%) and
5 PFO with 2HTTE (12.2%) (table 3A). There were one false
positive and two false negatives. Agreement was 92.7% with
Table 1 Characteristics of the population after randomization according to contrast agents.
Dextrose 
and air
Dextrose and 
air and blood
Hydroxy-ethyl-
amidon
p
Randomized patients (n, %) 41 (33.9) 33 (27.3) 47 (38.8) ns
Age (years±sd) 56.3±13.8 61.3±12 54.2±15 ns
Gender (n, %) Men 28 (31.1) 27 (30) 35 (38.9) ns
Women 13 (41.9) 6 (19.4) 12 (38.7) ns
Indication (n, %) Definitive ischemic cerebral event 17 (31.5) 15 (27.8) 22 (40.7) ns
Atrial arythmia ablation 16 (36.4) 13 (29.5) 15 (34.1) ns
Transient ischemic cerebral event 8 (47.1) 5 (29.4) 4 (23.5) ns
Distal leg ischemic event 0 1 (16.7) 5 (83.3)
Echocardiograph (n, %) Sonos 5500 19 (28.8) 18 (27.3) 29 (43.9) ns
Sequoia 256 22 (40) 15 (27.3) 18 (32.7) ns
Ultrasound window (n, %) Good 28 (34.6) 26 (32.1) 27 (33.3) ns
Medium 9 (27.3) 6 (18.2) 18 (54.5) ns
Bad 4 (57.1) 1 (14.3) 2 (28.6) ns
Table 2 Number of PFO’s diagnosed by echocardiogra-
phy irrespective of contrast agents.
TEE shunt TEE no shunt
TTE shunt 19 4 23
TTE no shunt 3 95 98
22 99 121
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a coefficient of agreement κ of 0.683 (good agreement).
Thus using the DA contrast agent, 2HTTE had a sensitivity of
66.7%, a specificity of 97.1%, a positive predictive value of
80%, and a negative predictive value of 94.4%.
Dextrose solution and air and blood (DAB)
TEE detected 10 PFO (30.3%) while 2HTTE detected 11 PFO
(33.3%) (table 3B). There was only one false positive and no
false negatives. Agreement between 2HTTE and TEE was the
highest of the three (97%), with a coefficient of agreement of
0.930 (very good). With DAB, 2HTTE exhibited a sensitivity of
100%, a specificity of 95.6%, a positive predictive value of
90.9%, and a negative predictive value of 100%.
Hydroxyethylamidon (HEA)
Out of 47 patients, we detected 6 PFO with TEE (12.7%)
and 7 with 2HTTE (14.9%), giving one false negative and
two false positives (table 3C). The agreement between
these two techniques was 93.6%, with a coefficient of
agreement of 0.732 (good agreement). With HEA, 2HTTE
exhibited a sensitivity of 83.3%, a specificity of 95.1%, a
positive predictive value of 71.4%, and a negative predic-
tive value of 97.5%. 
DAB was the contrast agent that gave the best agreement
(97%) between 2HTTE and TEE for the diagnosis of PFO
(p<0.05) (figure 1).
Semi-quantitative agreement 
between 2HTTE and TEE, 
irrespective of contrast agent
For 108 patients out of 121 (89.2%), 2HTTE was able to eva-
luate the shunt correctly compared to TEE irrespective of
the semi-quantitative grade of PFO (table 4). Nevertheless
we had 4 false positives and 3 false negatives. In addition,
among the 22 cases of PFO, there were 9 cases (40.9%) for
which the semi-quantitative evaluation of the shunt diffe-
red between 2HTTE and TEE. The Kappa test produced an
agreement between these two examinations of only 89.3%,
with κ=0.67 (good agreement).
Quantitative echogenicity 
of contrast agents
RVI was higher with DAB (3.6±1.6) than with DA (2.6±1)
(p=0.02) (figure 2). RVI was also higher with HEA (3.7±2.1)
than with DA (2.6±1) (p=0.02). On the other hand, there
was no difference in RVI between DAB and HEA (p=0.8).
Similarly, we obtained identical results in a pairwise com-
parison of the medians, and there was no difference in RVI
between DAB and HEA (p=0.79) (results not shown). DAB
and HEA developed higher contrast gain than did DA.
There was little discordance between the two investiga-
tors after the second reading of each examination. In only 6
TTE examinations out of 121 (4.9%) was there doubt about
whether or not there was an interatrial shunt and in all
these cases, the ultrasonographic window was either poor
or medium. In TEE, there was doubt in 2 cases out of 121
(1.6%). This is a lower discordance rate than that reported
in other studies, perhaps due to differences in the power of
the echographic or recording systems used. There were
Table 3 Number of PFOs diagnosed by TTE and / or TEE
with dextrose and air (3-a) dextrose and air and blood
(3-b) or hydroethylamidon (3-c).
A. Dextrose and air
TEE shunt TEE no shunt
TTE shunt 4 1 5
TTE no shunt 2 34 36
6 35 41
B. Dextrose, air and blood
TEE shunt TEE no shunt
TTE shunt 10 1 11
TTE no shunt 0 22 22
10 23 33
C. Hydroxyethylamidon
TEE shunt TEE no shunt
TTE shunt 5 2 7
TTE no shunt 1 39 40
6 41 47
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Figure 1. Qualitative agreement between TTE and TEE according
to the contrast agent: DAB gave better agreement (97%) than DA
(92.7%) or HEA (93.6%).
*: p<0.05 from DA.
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Figure 2. Box and whisker plot. For each contrast agent, the
horizontal line and the written value represent the median (50th
percentile) RVI. The box extends from the 25th percentile to the
75th percentile. Whiskers correspond to minimal and maximal
adjacent values. There was a higher contrast gain with DAB or
HEA than with DA.
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6 cases of discordance among the 22 shunts (27.3%) hinging
on the semi-quantitative measurement of the shunt, (simi-
lar to the reported rates).
Furthermore, there was no difference in echograph use
with the different contrast agents. 
Discussion 
Systemic ischemic events, particularly in the brain, usually
require a Doppler echocardiographic examination to detect
an embolic process. However, reliable and complete dia-
gnosis does not seem possible using just transthoracic echo-
cardiography in fundamental imaging mode and invasive
TEE is practised [12, 14, 17-19]. There has been considera-
ble interest in developing less invasive techniques such as
2HTTE, which we evaluated here for detection of PFO.
2HTTE does not necessitate sedation of the patient, does
not require evaluation by paramedical personnel, and is
quicker. There is no contraindication for 2HTTE. We choose
the cough maneuvre for shunt sensitization because it is
easier than the Valsalva maneuver. Our results demonstrate
that 2HTTE is useful as it gives good agreement with TEE
(κ=0.81), especially when DAB is used as the contrast agent
(κ=0.93). False positive and false negative results may
occur with intrapulmonary shunts. Furthermore, in a video-
densitometric study, we obtained higher intensity images
with DAB and HEA than with DA.
Fundamental transthoracic imaging has tended to be
superseded by the transesophageal technique for PFO
detection. Pearson et al. showed that TEE more frequently
identified atrial septal aneurysm associated with a PFO
than did fundamental TTE (9 versus 1 of 79 patients,
p<0.05) [12]. In other studies, PFO was detected by transe-
sophageal echography in 20 (53%) out of 38 patients, com-
pared with just 9 (24%) out of 38 by transthoracic imaging
(p<0.05) [10].
2HTTE has now supplanted fundamental TTE imaging for
left ventricular echographic measurements as well as for
endocardial definition or dobutamine stress echocardiogra-
phy [20-22]. However, few studies have focussed on 2HTTE
in PFO detection [20-22]. In the study of Kühl et al. on 111
patients with ischemic cerebral embolic events, 52 showed
evidence of a right-to-left atrial shunt with 2HTTE compa-
red with only 32 with fundamental imaging (p<0.001) and
51 with TEE (p=ns) [23]; furthermore the severity score of
the shunt did not differ between 2HTTE and TEE (61.6±80.2
bubbles versus 43.9±54.3 bubbles; p=ns). In the study of
Madala et al. on 64 patients referred for TEE after ischemic
cerebral attack, TEE identified 9 PFO; for 2HTTE the sensi-
tivity was 100% and the specificity was 82%, whereas for
fundamental TTE sensitivity and specificity were 78% and
100% respectively [24]. Ha et al. showed that 2HTTE using
contrast agents was superior to TTE using fundamental ima-
ging for detecting PFO in 136 successive patients referred
for the investigation of a cardiac embolism source. The two
methods had comparable sensitivity and specificity [25].
Our randomized prospective study on 121 patients also
referred for PFO detection by TEE, indicated that 2HTTE
was effective with a very good agreement of 94.2% (κ=0.81)
with the TEE results. The sensitivity, specificity, positive
predictive value, and negative predictive value, were res-
pectively 86.4%, 96%, 82.6%, and 96.9%.
A variety of contrast agents have been employed for
echocardiographic examinations to highlight right and left
heart cavities [26]. Several studies have concluded that
injection of contrast agent optimized detection of a cardiac
shunt [19, 27, 28]. We tested three contrast agents in both
2HTTE and TEE: DA solution, in routine use in our depart-
ment; DAB solution (as the addition of blood has been used
with success in other circumstances [29, 30]); and HEA solu-
tion as its physicochemical characteristics appeared well
suited for second harmonic imaging. We did not test saline
because its chemical composition is too similar to that of
blood to generate enough contrast. A polygelatin solution
employed in two studies published while our study was
underway gave excellent opacification of the right cardiac
cavities. Kuhl et al. used a polygelatin solution (Gelifundol,
Biotest Pharma) [23], while Tan et al. showed that agitated
colloid was superior to saline for opacification of right heart
chambers in 25 successive patients [31].
Our TTE results show that DAB gives the best agreement
with TEE, with a similar PFO diagnosis rate (97%, i.e. only
3% of overestimated error) and a negative predictive value
of 100%. We noted a better contrast/noise ratio with DAB
than with the other two contrast agents. Thus, with this
contrast agent, an absence of atrial right-to-left shunt on
2HTTE would obviate the need for TEE to investigate PFO.
It should be borne in mind that PFO detection is seldom the
Table 4 Semi-quantitative agreement between TTE and TEE. Out of 22 PFOs, 13 (59.1%)
were evaluated with the same precision by TTE and TEE.
All contrast agents TEE no shunt 
grade 0
TEE shunt 
grade 1
TEE shunt 
grade 2
TEE shunt 
grade 3
TTE no shunt 
Grade 0
95 1 2 0 98
TTE shunt
grade 1
3 6 0 0 9
TTE shunt
grade 2
1 3 4 2 10
TTE shunt
grade 3
0 1 0 3 4
99 11 6 5 121
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only reason for performing TEE which is of value in the
search for other causes of systemic embolism, such as an
intracardiac tumor, thrombi or thoracic aortic disease.
Limitations
As in other applications, the ultrasound window limits the
usefulness of 2HTTE, especially in subjects with respiratory
diseases. But we demonstrate relevance of 2HTTE even in
subjects with a medium ultrasound window. TEE diagnosed
only 22 PFO (18.2%) in our population, which is lower than
the usual prevalence in the general population [32] or in
the population of stroke patients [1, 33-35], low-powering
our study. This can be accounted for by the fact we only
had 63% ischemic events in our population; indeed, the
indication of TEE before ablation of atrial fibrillation redu-
ced the potential number of patients with PFO. The right
atrium was selected for acquisition of the digitized pictures
as the contrast agent concentrates in this cavity after injec-
tion into the peripheral venous circulation, and also
because this is the site that is most often analysed in stu-
dies on contrast agents [29, 30]. Even if there is not yet a
real-life clinical application, calculation of the relative
variation of intensity effectively eliminated measurement
errors due to background acoustic noise and differences in
gain settings from one examination to another. Comple-
mentary studies with larger samples should show higher cli-
nical relevance. The main error in this phase of the study
stemmed from the positioning of the sampling window to
measure the contrast intensity: the 10 mm window was
positioned arbitrarily by the investigator on the least echo-
genic zone of the right atrium before injection, then on its
most echogenic zone after injection. As mean or median,
DAB and HEA were much more echogenic than DA, which is
usually employed in PFO investigation. There was no diffe-
rence in intensity between DAB and HEA and either onis sui-
table for PFO detection. Moreover, DAB has no added cost
as it is derived from the venous perfusion solution.
Conclusion
When performed using a contrast agent, TEE and 2HTTE
had comparable yields for PFO detection. Thus, PFO could
be initially investigated using 2HTTE with DAB as the con-
trast agent, with a sensitivity of 100%, a specificity of
95.6%, a positive predictive value of 90.9%, and a nega-
tive predictive value of 100%. In stroke patients, TEE is
usually required to explore the atrial septum as well as
the left atrial auricle and the thoracic aorta. However, in
selected patients such as those studied before spinal sur-
gery or after PFO closure, PFO can be reliably diagnosed
by 2HTTE.
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